Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Should CYP2C19 genotype testing be performed in patients presenting with ISR on Plavix?
Related Questions
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
How do the results of CREST-2 influence your recommendations on screening for asymptomatic carotid stenosis?
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
What are your top takeaways from the updated ACS guidelines that will inform changes in clinical practice?
How do you approach the decision of when to perform left heart catheterization in a patient with an NSTEMI who recently had an acute ischemic stroke?
What neurologic and hemodynamic parameters do you use to determine candidacy for emergent cath lab activation following out of hospital cardiac arrest from VT/VF in patients with NSTEMI after ROSC has been achieved?
What is your stepwise approach to managing no re-flow during PCI?
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
